Sort
30,917 grants matching “tumor microenvironment”
Project 2- The ISR effector ATF4 in metabolic reprogramming and survival during Myc-induced tumorigenesis
$288,048Constantinos Koumenis · University Of Pennsylvania · P01 · FY2021 · CA
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
$288,035Parijat Bhatnagar · Sri International · R21 · FY2016 · CA
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced
$288,007Soldano Ferrone · University Of Pittsburgh At Pittsburgh · P50 · FY2013 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$288,000Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$288,000Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$288,000Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$288,000Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$288,000Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$287,999Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2023 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$287,999Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2025 · CA
P-4: Targeting activation of NFkB pathways in MM
$287,967Peter Leif Bergsagel · Dana-Farber Cancer Inst · P50 · FY2010 · CA
Core 2: Biospecimen Core
$287,956Ruth Halaban · Yale University · P50 · FY2018 · CA
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer
$287,952Edmund C. Lattime · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2011 · CA
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1
$287,949Joseph S Pagano · Univ Of North Carolina Chapel Hill · P01 · FY2018 · CA
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1
$287,947Joseph S Pagano · Univ Of North Carolina Chapel Hill · P01 · FY2020 · CA
To Understand/Augment OX40-mediated Tumor Immunotherapy
$287,887Andrew D Weinberg · Providence Portland Medical Center · R01 · FY2013 · CA
PSK as Neoadjuvant Therapy for Locally Advanced Breast Cancer
$287,877Hailing Lu · University Of Washington · R01 · FY2010 · CA
Project 2- The ISR effector ATF4 in metabolic reprogramming and survival during Myc-induced tumorigenesis
$287,854Constantinos Koumenis · University Of Pennsylvania · P01 · FY2023 · CA
Effect of Tumor Derived TGF B on Dendritic Cell Vaccines
$287,850University Of Arizona · R01 · FY2005 · CA
Integrative Cancer Scholars Training Grant
$287,821Jennifer S Carew · University Of Arizona · T32 · FY2024 · CA
CD4+ Memory T-Cells in Human Tumor Microenvironment
$287,818Richard B Bankert · State University Of New York At Buffalo · R01 · FY2014 · CA
Models of EBV Cancer
$287,773Samantha Standish Soldan · Wistar Institute · P01 · FY2024 · CA
MUC1 Roles in ovarian cancer pathogenesis and immune therapy
$287,764Anda M Vlad · Magee-Women'S Res Inst And Foundation · R01 · FY2015 · CA
Tumor Necrosis Factor Modulation of CPCs
$287,753Sumanth D Prabhu · University Of Louisville · P01 · FY2011 · HL
Project 2- The ISR effector ATF4 in metabolic reprogramming and survival during Myc-induced tumorigenesis
$287,660Constantinos Koumenis · University Of Pennsylvania · P01 · FY2020 · CA